

**RECORDATI: PUBLICATION OF DOCUMENTS RELATING TO THE ORDINARY AND EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 29.04.2026**

Milan, 27<sup>th</sup> March 2026 - Please be informed that the following reports approved by the Board of Directors of Recordati S.p.A. on 19<sup>th</sup> March 2026:

- (i) the **Report on the 2026 Remuneration policy and the remuneration paid for 2025**;
- (ii) the **Directors' Reports relating to the following items of the agenda of the Ordinary and Extraordinary Shareholders' Meeting** called for the 29<sup>th</sup> April 2026:

**Ordinary session**

- item no. 3 - (Report on the Remuneration policy and the remuneration paid) which includes, as its annex, the Report on Remuneration policy and the remuneration paid referred to in point (i);
- item no. 4 - Approval of the "2026-2028 Performance Shares Plan", including the related Information Document drawn up pursuant to art. 84-bis of the Regulation approved by CONSOB with resolution no. 11971 of 14 May 1999, as subsequently amended and integrated;
- item no. 5 - Authorization to the purchase and disposal of treasury stock;

**Extraordinary session**

- item no. 1 - Delegation of authority to the Board of Directors pursuant to Articles 2420-ter and 2443 of the Italian Civil Code.

are available to the public, as of today, at the Company's registered office and published on the Company's website ([www.recordati.it](http://www.recordati.it), the first report in the Governance - Remuneration section; and the other reports in the Investors - Shareholder Information section) and on the '1INFO' storage mechanism ([www.1info.it](http://www.1info.it)).

***Recordati** is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of "unlocking the full potential of life" aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.*

**Investor Relations**

Eugenia Litz  
[Eugenia.Litz@recordati.com](mailto:Eugenia.Litz@recordati.com)

Gianluca Saletta  
[saletta.g@recordati.it](mailto:saletta.g@recordati.it)

**Media Relations**

Laura Conti  
[conti.l@recordati.it](mailto:conti.l@recordati.it)

Rebecca Kerr  
[rebecca.kerr@recordati.com](mailto:rebecca.kerr@recordati.com)

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered office  
VIA M. CIVITALI, 1  
20148 MILAN, ITALY  
TEL. +39 0248787.1  
FAX +39 0240073747

SHARE CAPITAL € 26,140,644.50 fully paid up  
BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI 00748210150  
TAX CODE/VAT NO. 00748210150  
MILAN ECONOMIC AND ADMINISTRATIVE INDEX (REA) 401832

Company subject to management and coordination by Rossini Luxembourg S.à.r.l